OmniAb, Inc. (OABI) Earnings Call Transcript & Summary
May 7, 2026
Earnings Call Speaker Segments
Kurt Gustafson
executiveThanks, Derek, and good afternoon to all of you. We appreciate everyone being here for the conference call on our financial results for the first quarter of 2026. Slides have been prepared to go along with the remarks we've prepared for today, and you can find them in the Investors section on our website, omniab.com. Before we get started, I want to let those listening know that anything said on this call by OmniAb's management will contain forward-looking statements as defined under the federal securities laws. Risks and uncertainties are part of these forward-looking statements, and they could result in actual results differing materially from any results that are anticipated; the cautionary statements in today's press release and our SEC filings qualify these forward-looking statements. It's important to note that time-sensitive information is included in this conference call, and it is accurate only as of today's live broadcast date, May 7th, 2026. OmniAb assumes no obligation, except as the law requires, to revise or update any forward-looking statements so they reflect events or circumstances occurring after this call's date. With me this afternoon is OmniAb's President and CEO, Matt Foehr. Some of the business highlights are going to be covered by Matt. Our Q1 financial results and full year guidance will be reviewed by me, and after that we'll open up the call to questions; so, I'll hand things over to Matt.
Matt Foehr
executiveAppreciate that, Kurt. Hello, everybody, and thanks for being here on our Q1 call. I'll begin on Slide #4. OmniAb is off to a really impressive start this year, with most of that momentum coming from progress in our partners' programs. We keep watching programs built on our technologies enter clinical testing and advance toward later phases; and quite often, in a lot of ways, that's the point where our business model turns into tangible, easier-to-see value for those with a stake in the company. As these programs keep moving forward, we gain an increasingly clear view of what future milestone payments and fresh royalties could look like when our partners' programs progress. We believe our company is set up to benefit from durable revenue streams, and from our perspective, royalty payments linked to differentiated pharmaceutical products carry substantial worth. Beyond that, the breakthroughs and technologies we've developed are designed to distinguish OmniAb as a licensing collaborator and, more broadly, as an organization, and they keep us at the forefront of next-generation discovery technology. We feel our innovative technologies and our processes are ever more capable of drawing in partners, while continuing to serve existing relationships, with potentially significant effects on both our business and our industry. Our OmniUltra and OmnidAb technologies alike are unlocking fresh markets and possibilities, and the momentum we're witnessing is heartening. We think one of our biggest competitive edges comes from innovating, and that innovation is shaped by the close ties we maintain with partners. In Q1, we kept working to lay a solid groundwork for xPloration, since we see it as a huge chance to broaden our customer base and bring in revenue from more varied sources. Our xPloration sales pipeline keeps expanding, with many promising potential customers assessing the system for their lab needs, and because the year has begun so well, we've updated our guidance for the full year and raised our revenue forecast — something we see as a meaningful early sign of the worth contained within our partner pipeline. Kurt will go into more depth about the revised guidance when he shares his comments. Moving on to Slide #5, I want to spend a bit of time discussing a few of the innovative technologies we've brought to market, which we think set us up for future growth. OmniAb stands alone globally as the sole enterprise possessing a transgenic chicken platform capable of generating antibody sequences that are entirely human. One benefit that comes from using chickens stems from how far they sit from mammals on the evolutionary tree when serving as a biological host for discovery; because of that separation, our birds can mount a strong reaction and produce a wide-ranging collection of antibodies targeting new targets that would probably not work in a mammal. Our business development colleagues were recently in San Diego for the AACR conference. During the conference, several reports came out—one in particular from BioCentury—indicating that roughly 170 fresh therapeutic targets for cancer were unveiled at the meeting, and a large number of those had never previously shown up in R&D programs centered on cancer. When targets are new, the biology behind them is usually not yet completely understood, which is exactly where technology platforms such as ours can truly help by clarifying things and advancing the discovery of novel drugs. A large number of drug targets have tended, over time, to stay remarkably similar among mammals, which makes the case for our transgenic chicken platforms even stronger. We've developed multiple separate lines of chickens that are heavily bioengineered, and these birds can produce distinctive antibody collections and assist in finding medicines — among them standard heavy and light chain antibodies, common light chain formats, single-domain antibodies, ultra-long CDRH3 domains, dual modality antibodies, and peptides as well. Every one of these platforms was built with the goal of unlocking new markets and getting partners more involved. Take our latest offering, OmniUltra, which you can see in the top right corner of the slide — it's the first transgenic chicken, and the only one, that can make antibodies featuring ultra-long CDRH3s, something you'd normally only see in bovine antibodies. The purpose of those ultra-long CDRH3s is to reach binding pockets that are beyond the grasp of any other antibody or modality, potentially paving the way for new therapeutic options. Beyond that, they might be valuable in areas like multispecific components, as binders for CAR-T and radiopharma, or as peptides produced in vivo. We launched OmniUltratech this past December. Then, in the coming week, our researchers will give presentations about OmniUltra at the PEGS Protein Engineering Meeting in Boston, and also at the TIDES peptide conference, which takes place in that same city next week as well. Prior to OmniUltra, the last new chicken-based platform we commercialized was OmnidAb, our single domain approach, introduced only a couple of years ago. By Q1, two partner programs derived from OmnidAb have entered human clinical trials. Each got to the clinic extremely fast, and one has already advanced into Phase II. I'll cover this in greater detail on a few upcoming slides while walking through our clinical pipeline. On Slide 6, you'll see an overview of xPloration. This is our own high-throughput platform for screening individual B cells, and it draws on machine learning along with artificial intelligence. The offering pairs an instrument priced to compete in the market with single-use consumables that we control exclusively. Because of that structure, it could open up several different revenue streams for our company. There's still a lot of enthusiasm around exploration, and people keep asking for demos because it runs fast, it's simple to operate, and it holds up well. Those advantages make us confident we've got the right technology at the right moment, since our partners and the wider industry are increasingly seeing how much lab automation matters, along with high-value, high-impact instruments that enable large-scale data generation plus AI- and ML-driven screening and selection. xPloration is still in its early days, but we're genuinely excited about the contribution this technology can make to the business. Now I'll go over a few of our metrics, beginning with Slide #7. When Q1 wrapped up, our count of active partners stood at 107, which matches where things landed at the close of 2025. During that first quarter, the new licenses we signed featured a deal with Florida State University, and we keep witnessing expanding chances within academia through contracts structured ahead of time with financial provisions enabling us to participate in the value of assets derived from our technology. Partner additions during this quarter were canceled out by attrition, something we anticipate as a normal aspect of how we operate. The balance among partners spanning discovery-stage firms, big pharma, and academic organizations stays quite even. Most of the partners we work with have their headquarters in the United States, while the rest are mostly based in Europe and Asia. We also take pride in the fact that 8 out of the 10 biggest drugmakers globally count as active OmniAb partners. That speaks to the caliber and durability of the partner group we've built and offers further proof of our technology platforms' value. And I believe it's somewhat worth pointing out that these are businesses spending billions of dollars on clinical trials plus research and development; thus they're putting significant capital to work finding medicines with real impact that reach worldwide markets, and they rely on OmniAb's technologies within their discovery operations. Our leadership and the whole team feel proud of this, so we think it deserves mention; I'll now turn to Slide #8, where you can view our active programs metric.
Matt Foehr
executiveWe wrapped up the quarter with 409 active programs, and the net increase reflects a combination of things — new programs being added, new program starts, and the usual attrition that happens when partners tighten up their pipelines and portfolio priorities. The key point is that roughly 98% of the programs we have active carry contracted future economics to OmniAb. Looking across the whole portfolio, total contracted milestones on standard antibody licenses come to more than $3 billion, with an average contracted royalty rate of about 3.4%. Now on the clinical side, Slide 9 lays out our partners' active clinical programs along with approved products. When Q1 closed, 32 active clinical programs and approved products were leveraging our technologies. This metric accounts for people newly joining the clinic as well as those who leave; I should point out that any figure we consistently share with investors has already had attrition subtracted from it. As I mentioned briefly, another program built from OmnidAb entered Phase I human trials this quarter, which adds to the momentum our newer technologies are generating, and we continue to anticipate several new clinical entrants in 2026; so far this year we've observed substantial clinical progress across these active clinical programs and expect further positive advancement activity before the year is out; also worth noting, approximately $350 million in potential contracted milestones still owed to OmniAb are linked to these clinical stage programs. Let's turn to Slide #10 now. This chart gives an overview of the active programs in our partner pipeline—both clinical and commercial stage—that bring downstream economics to OmniAb. Where a program appears here is based on whichever stage is furthest along, whether you look across geographies or indications. You can likely tell there's been quite a bit of shifting in the more advanced phases, since more programs have now reached Phase I, Phase II, and Phase III. I recognize that a lot of investors follow this chart and refer to it regularly, and I'd like to highlight several Q1 items that are central to what's powering parts of the business. To start, on the bottom left area of the current slide, within the Phase I portion, you'll notice that a second program based on OmnidAb has now moved into testing with humans; because of competitive considerations, this collaborator prefers to keep both the therapeutic target and their clinical activities private. Naturally, we honor that request from our partner. Looking further to the right side of this graphic, I'd like to point out that during Q1 we additionally saw one program advance from Phase I into Phase II. That one likewise stems from OmnidAb, and it's another case in which the partner still wishes to keep the program, and in particular the antibody's origin, confidential. On the OmnidAb single domain platform, these two programs rank as early adopters, and that's genuinely encouraging to witness. Each one is going after an area where, in our view, medical need remains largely unmet. Moving over to the right side, there's another item worth flagging: Ramantamig, which used to be called JNJ-5322, has been shifted upward on this chart from Phase I into Phase III. Earlier, J&J Innovative Medicines had put a spotlight on that program together with some impressive clinical data, and it's a trispecific antibody being developed for multiple myeloma. Medicines we consider to hold meaningful first-in-class or best-in-class promise are making that right-hand section of the graphic more and more packed. There's another item I'd like to highlight — the anti-IL-15 asset known as TEV-408. It drew a lot of attention in Q1, when Royalty Pharma poured a substantial sum into the program, something Teva announced during that quarter. When Teva held its latest earnings call last week, the company put this program front and center, pointing to its potential spanning multiple indications and describing it as moving along an "accelerated path". A summary of a number of upcoming clinical and regulatory milestones appears on Slide 11, and 2026 is plainly shaping up to be a truly packed year for news and catalysts among the clinical-stage programs of our partners. Among the data readouts Teva expects is one for TEV-408 in vitiligo, anticipated during the first half of the year. You know, that drug's currently being tested in a 24-week proof-of-concept trial. The main goal there is a body surface area score at week 24 — Teva refers to that as the registrational endpoint for this condition. As we move into the back half of the year, we're expecting more data readouts from Teva, from Merck KGaA, and from Immunovant's IMVT-1402 program, which is another really promising one that covers several different indications. And then on my last slide, Slide #12, we highlight a few of the partnered programs that'll be showcased at the ASCO conference, which kicks off later this month in Chicago. Those programs involve various cancer types and use antibody drug conjugates and bispecific antibodies developed from our technologies. We can't wait to get those results, since they ought to provide more transparency around each individual asset while continuing to demonstrate the strength of our extensively validated technology platform. On that note, I'll turn things over to Kurt, who'll walk through how we performed in Q1 along with our revised outlook for 2026. Kurt?
Kurt Gustafson
executiveAppreciate it, Matt. Like Matt said, we had a robust quarter, propelled by the strides made across our partner portfolio. I'll begin on Slide 14, covering total revenue. We brought in $14.4 million in total revenue, versus $4.2 million during Q1 of 2025. Growth came mainly from greater milestone revenue, which mirrors how our partners' clinical programs are advancing. Service revenue also rose modestly, thanks to a few new Ion channel deals that were signed late in the prior year and early in this one. Royalty and xPloration revenue stayed roughly flat compared to a year earlier. Now on Slide 15, you can see what we spent on operations this quarter; we're still carrying out our strategy of running things efficiently while still putting suitable money into our technology platforms. Operating expense for Q1 dipped a little, landing at $22.3 million, down from $23 million. The bulk of that drop comes from reduced personnel costs and lower outside service costs tied to contract research services plus legal expenses. Q1 2026 additionally carried a noncash write-off of $2.9 million tied to certain legacy small molecule ion channel intangible assets. Strip that out, and our operating expense decline versus the prior year would have looked even bigger. Slide 16 presents the shift in a new financial metric we rolled out last year: cash cost and operating expense. Our definition is GAAP cost and operating expense minus stock-based compensation along with depreciation and amortization of intangibles. Basically, you take the GAAP figure and strip away all the significant noncash items sitting in our P&L. We think this metric gives a clearer picture of what we actually spend. As this slide shows, although both the GAAP and non-GAAP numbers fell, the drop in our cash operating expense was even steeper. We're focused on finding efficiencies in the business that have pushed costs lower. However, in Q1 2026, because of that noncash write-off, those savings don't stand out as much if you only look at GAAP figures. Moving along, Slide 17 lays out our P&L for the quarter. I want to point you toward our operating expense line items, where cuts to R&D and G&A show what cost savings and other efficiency efforts have delivered. R&D fell $3 million, reaching $9.6 million in Q1 of 2026, while G&A likewise fell $1.3 million, reaching $6.6 million in Q1 of 2026. That onetime noncash charge I referenced earlier showed up in the goodwill and intangibles amortization line. Net loss for Q1 of 2026 came to $7.7 million, or $0.06 per share. That's against a net loss of $18.2 million, or $0.17 per share, in the comparable period a year ago. If you set aside the onetime noncash charge, our EPS for Q1 2026 would have been a loss of $0.04 per share. Now let's look at the balance sheet on Slide 18; we closed the quarter holding $49.1 million in cash. Additionally, you're going to notice a modest bump in our receivables, which mirrors the milestone accomplishments from this quarter that payment for won't arrive until the following quarter; our belief remains firm that this company holds sufficient capital to carry out our strategy. Slide 19 contains our refreshed 2026 financial guidance, capturing both the robust Q1 results and how we see the rest of the year unfolding. Our outlook for full year 2026 revenue is being lifted, and we're adjusting what we expect for operating expenses as well as cash at year-end. Total revenue for 2026 is now projected by us to land between $28 million and $33 million. In Q1, a milestone outside our initial guidance was reached by one of our partners, and that's the main factor behind our raised revenue guidance; GAAP operating expenses for 2026 are now expected by us to fall between $83 million and $88 million. This updated range stems chiefly from the noncash impairment charge we booked during the first quarter. Crucially, guidance for cash operating expenses stays the same, at $50 million to $55 million, since the noncash write-off has no effect on that number. Turning to cash: because revenue should be higher and cash operating expense guidance hasn't moved, we now expect to finish 2026 holding cash and cash equivalents somewhere between $33 million and $38 million. Our full-year effective tax rate stays at roughly 0%, thanks to the valuation allowance we carry. I figured it would be useful to place our guidance in historical context, which is what Slide 20 does. Our 3-year financial metrics, as you can observe, are trending better, especially regarding how much cash we use. Versus 2025, we anticipate substantial revenue growth in 2026, even as cash operating expense should stay within a narrow range, pushing total cash consumption downward. We remain in a stretch where milestones largely dictate revenue, and those can swing wildly from one quarter to another, yet our lineup of partner programs keeps expanding and moving forward. Generally speaking, that ought to push milestone revenue upward. Looking past the coming couple of years, we'd anticipate royalty revenue arriving and beginning to speed up that revenue expansion, ultimately contributing a bigger share of our overall revenue. Royalties stacking on top of infrastructure that scales—that captures the core of our business model and signals a bright future for both this company and its shareholders. Having said all that, I'd now like to take questions. Operator?
Joe Pantginis
analystTwo things, if I may. First, you said a few of your partners have ASCO data on the way. Do those readouts carry any milestones with them? And secondly, are they baked into the guidance you've given? Then the second item, more broadly on your technology platforms: you keep building new ones, so could you talk about — no need to reveal trade secrets — any tweaks or upgrades you're making to the platforms you already have that make them easier to sell?
Matt Foehr
executiveYes. Great. Thanks, Joe. Yes, good questions. On the ASCO data events, perhaps the way to address that is to explain in general terms how we structure our agreements, right? Partners approach us seeking access to our technologies, and typically we sign a license agreement giving them that access in return for service costs, certain license fees, and then the main piece, which is downstream milestones and royalties. And although we usually begin at roughly the same point in any negotiation with our 107 partners, no two agreements look identical in some respect. But by and large, milestone payments tie to clinical events, regulatory events, approvals, that sort of thing. So mostly, it's Phase I starts, Phase II, Phase III. There are a few nuances involved. Typically we don't hold milestones tied specifically to, shall I say, data disclosures, though milestones tied to data generation can exist. So hopefully that adds a bit more color there. As for ASCO, we're genuinely enthusiastic about some of the work our partners will present. I view that as a chance for assets to come more sharply into focus for those tracking the expansion and growth of our portfolio; on the technology platform side, clearly, I covered several of our platforms today during the prepared remarks, particularly our chicken-based technologies. And it's worth noting, even past our night branding of each of those technologies — our brand team is clearly proud of that — even underneath, there are distinct highly technical subflavors, so to speak, of each of those animals that we match with partners' programs; and I believe that's part of why we've kept succeeding at growing the portfolio, why partners sort of grasp the quality of the technologies we make. And for us, those ongoing innovations and the things we layer on truly come from these deep relationships with our partners. So really drawing on this ecosystem of partnerships and these deep relationships around discovery, that shapes our ongoing innovation. And we anticipate we'll keep innovating around our platforms, and another area I'll point to is workflows too. We keep pushing forward on making workflows more efficient, using big data management, AI and ML, plus our data work and similar efforts—partners have recognized that about us for years. Yet when you put all those pieces together, I believe you'll keep seeing that type of innovation coming from us down the road.
Srikripa Devarakonda
analystThere were two things I wanted to ask about. First, regarding Teva and TEV-408 — with Phase Ib vitiligo results anticipated during the first half, and Matt, you were just mentioning it — on the milestone question, would payment only come once Teva officially decides to advance the program into Phase II or Phase III, or does a milestone trigger at the close of Phase Ib, once we know they're proceeding? Then the second item: Immunovant recently reported that batoclimab did not succeed in Phase III trials for TED. For at least some investors, that had been among your most advanced and visible programs. Could you discuss how this affects your longer-term royalty projections, given that you also have Immunovant's IMVT-1402?
Matt Foehr
executiveYes. Great. Perhaps I'll take your second question first, Kripa, regarding Immunovant. For quite some time, they've stayed sharply focused on quickly moving IMVT-1402 through clinical development; that's really been their signal over roughly the last couple of years. Of course, IMVT-1402 is an investigational FcRn blocker. They're evaluating it in a range of autoimmune diseases where there's considerable unmet medical need. Graves disease ranks among their main strategic priorities. But beyond that, they're pursuing several other diseases with IMVT-1402 too. So alongside Graves, they're examining difficult-to-treat rheumatoid arthritis and lupus, where they believe the drug could potentially be first-in-class and best-in-class. They're also looking at myasthenia gravis, CIDP, and Sjogren's disease, which they've typically characterized as a potential best-in-class therapy. So we've genuinely observed — and they've made clear — that shift toward IMVT-1402 for a good while now. As a result, the Batoclimab news that came out truly didn't affect our planning, our guidance, or anything of that sort. So naturally, we're rooting for them and all the excellent work they're doing on IMVT-1402. Turning a bit to your question about TEV-408 at Teva. Although I'm unable to reveal the final specifics of any particular contract, I'll refer back to what I said earlier about how our agreements tend to be structured in general — but that asset, I believe, is drawing considerably more attention at this point. It's something they're emphasizing quite a lot. They've characterized it as having a rather unique binding site. They refer to it as the antibody with the highest affinity for IL-15, and they're pursuing several indications. At present, that includes vitiligo and celiac. Vitiligo carries truly enormous unmet medical need, with substantial psychosocial burden, social stigma, and so forth, and they'll report top line results from that in the first half of the year. They also have a trial underway in celiac. And more recently, they've mentioned additional indications for this as well — alopecia areata, atopic dermatitis, eosinophilic esophagitis, and potentially others too. So obviously, we're cheering them on. It's wonderful to witness how quickly they're moving clinical programs forward, and in a few of their recent presentations they've also discussed possible market size, mentioning a potential for peak sales of $1 billion in vitiligo alone and $1.5 billion to $2 billion in celiac; so we're rooting for them too. Plus, they've been a fantastic partner for us over the long term. So that's nice to see.
Jacqueline Kisa
analystThis is Jackie sitting in for Brendan. Perhaps a wider question to kick things off for us; we've noticed plenty of pharma and academic users boosting their own uptake of AI in their workflows. So how ought we to think about the way that adoption ramp should affect demand for your particular products and services? Do you anticipate that growth in partner model training might possibly speed up demand for your platform, which generates so much data?
Matt Foehr
executiveYes. Thanks, Jackie. Yes, good question. Put simply, we view AI as a tailwind for the industry, a genuine positive for many different reasons. To start, plenty of accounts have come out about AI helping to accelerate how soon new targets might be spotted. And I'd say we're seeing some preliminary signs of that in a few developments from this year's AACR meeting, which I brought up in the prepared remarks — more than 170 oncology targets that hadn't been tracked before are now coming into view. Our partners have been aware of us for quite some time, and if you review our record of announcements and so on, we've been putting AI to work for a good while. Our involvement here has been substantial — given novel biological systems producing countless sequences, moving in this direction made obvious sense for us. A few years back, we introduced something called OmniDeep, a platform that basically serves as an umbrella brand for the computational tools embedded across our whole technology stack. I've shared this anecdote a few times before, and seeing this partner again recently brought it back to mind. A partner once spoke with me, describing how well things were going with our platform, and mentioned how much remains unknown about novel biology. That's particularly true when pursuing a disease target that isn't fully understood. She likened the target biology data available across all public databases—and even inside individual companies—to nothing more than a bathtub's worth of data, whereas chasing a novel target requires exploring the ocean. She was kind of framing our animals as a means of finding your way through that ocean — you're able to build these custom repertoires, and from there, further along, AI and machine learning become genuinely useful for concentrating your efforts, refining things, and handling work that comes afterward. So the effect AI will have throughout the industry is something we feel good about, and I'd say our position is quite strong.
Jacqueline Kisa
analystSo in that comparison, it's more Dolphin, less rubber ducky, I suppose. But perhaps — it could be too soon to say, yet just to follow up, are you noticing any change in new partner interest leaning toward more data and tech-focused partners, away from the pure biology plays? It might be too soon to say, but are you seeing any of that kind of mix shift over to tech?
Matt Foehr
executiveWell, I do — the remark I'll offer, and it sort of ties to our xPloration platform, is that I do believe there is — and it's part of why we feel xPloration is well timed. There's a thirst for more data, right, and big data analysis; and I think that was one of the things that partners saw in us and can see our technology platform developing and producing. So hopefully, that gives you some color.
Josh Nickerson
analystJosh here, filling in for Steve. You mentioned the new license that came from Florida State, and I realize you've talked before about sharing economics from partnerships of this type, but I'd like to go a bit further into how the economics differ between, say, a more academic arrangement and one that's more industry-focused, what those distinctions look like, and whether either type gets priority going forward.
Matt Foehr
executiveYes, good question. When we describe and actually build out the framework of our contracts with academic institutions, put simply, it's what we'd term a revenue share, correct? The reason they're built that way is precisely so that academics concentrating on monetizing assets or forming companies can do so, right? And we have witnessed that already — examples exist. Given certain forces at play across the broader academic world, I believe we'll see additional universities eager to spin companies out of some of their fundamental biology technology and similar work. So the structure involves revenue being shared that flows back to OmniAb, and that sharing can take multiple shapes: license fees, sublicense fees paid to a newly created entity, or equity in that newly formed entity, which would likewise come back to OmniAb. Then there are those sorts of situations, plus milestones and royalties too. These agreements are purpose-built to make that possible. In our view, that's fairly distinctive when it comes to licensing within academia, and I believe it does draw partners in. Some of the research conducted at these institutions is truly remarkable. I've been quite struck by what a number of our academic partners have generated — partners who, right from the outset, intend to potentially launch companies. Naturally, that requires time, but it's encouraging to witness. So with any luck, that provides you with a bit more insight.
Josh Nickerson
analystYes, absolutely. Then, just one more thing. I'm aware there was an earlier question regarding certain milestones tied to potential catalysts in this year's back half. So I'm simply considering your assumptions around milestone and license revenue for the rest of the year. Given that a few of these clinical event catalysts are approaching, would it be reasonable to say that perhaps a greater share of your milestone and royalty revenues lands in the back half, based on the guidance you gave?
Kurt Gustafson
executiveWell, my sense is that we gave revenue guidance covering the whole year. For us, Q1 came in fairly strong. The bulk of revenue earmarked for 2026 is, in a sense, tied to milestones. That tends to be uneven. So our Q1 was quite good, yet we're also looking ahead — we've essentially projected several favorable clinical events occurring across the remaining portion of the year. Thus we've begun well, though we anticipate additional developments.
Michael Almisry
analystPuneet couldn't join us, so Micheal Sonntag is filling in for him. Congratulations on the quarter. I'd like to start with OmniUltra. As you move into additional customer categories and modalities — peptides being one example this model opens up — is there anything you can tell us about the momentum you're observing? What details could you provide on that front?
Matt Foehr
executiveYeah, great. Thanks, Micheal. Absolutely — OmniUltra is without question the most recent technology in our lineup. As I mentioned, it came out just in December, and next week our team is going to showcase it at both the PEGS conference and the TIDES conference in Boston, and it opens up a large number of new possibilities for us. We're still in the early stages. The feedback has been positive, I would say. We already have several programs going with partners on OmniUltra—that's something we've shared publicly before. In the antibody field, the companies that are deeply familiar with OmniAb see this as a very logical next step, and we're actively engaged in a number of work plans, with additional starts expected before long related to OmniUltra. These are groups with interest in what I'd call the Pico body component, along with the ultra-long CDRH3 component that comes out of the OmniUltra platform. When it comes to peptides, this really represents an entirely novel approach to peptide discovery, correct? What you're doing is seeking out peptides that are naturally biologically active from the start, or screening for them immediately, and those peptides have also been developed for stability, so you end up with a lot of variety in those collections. That said, it's somewhat of a novel pitch, correct? These represent new buyers for us, which is fantastic. I think there's a genuinely good chance in that space; however, more than 130 businesses that weren't previously listed in our call file have now been added to it, and our BD team has been contacting them and engaging in conversations; so it's still early, but we're thrilled about it, and we're eagerly anticipating showcasing the OmniUltra technology at those conferences the following week too.
Michael Almisry
analystThen I also wanted to ask about the new program starts for this quarter. They arrived perhaps somewhat weaker than our expectations. And a bigger tool company, especially one tapping the preclinical space, did point to pressures in early-stage biotech that hurt its numbers. I'm wondering whether you can give any insight into whether you're noticing any of that, or whether this is simply the usual variability in starts.
Matt Foehr
executiveYeah. I would describe it as the usual variability, correct? We observe lumpiness when it comes to program additions. A substantial bolus of programs showed up extremely late in Q4. And at times there will be effects on the timing of when annual or biannual reports arrive from our partners. So that can be — that may also factor into it too. But no, we actually — what we see is the industry truly — a couple of years back, there were far more, I'll call them, macro pressures across the industry. What we're truly seeing now is the industry returning to work, and that has us excited. So I would simply characterize it as the sort of standard lumpiness we experience.
Tanay Mehta
analystIt's Tanay here, filling in for Mike. Nice work on the updates. I've got one quick thing about your active programs. You had 9 additions and 7 terminations, and that's the basis for this year's guidance. I just wanted to check: do the newer contracts carry more value than the older ones? Or could you give us a bit more detail on that?
Matt Foehr
executiveSure. When we look at our entire portfolio of programs, we have more than $3 billion in contracted milestones, plus an average royalty rate of 3.4%. If you consider what that average royalty rate looked like a couple of years back, it has genuinely gotten better with time. With a denominator that large, it can take a while for that to keep developing. But because we keep building a more validated platform and putting money into it, we've been able to secure, I'd say, strong economics. The way additions and starts of programs happen, they tie to a specific partner and a contract; so they aren't always tied to something you'd describe as just signed within the last quarter or so, correct? A number of the programs about to spin up come from an agreement that might have been signed a couple of years back, correct? So you get quite a mix there. Still, I'd point back to our total portfolio in that regard. That said, we're enthusiastic about the novel targets our partners are pursuing; we're seeing larger companies take larger swings, so to speak, when it comes to target and indication; and I believe that's encouraging to watch, it's a healthy sign, and it's something we're enthusiastic about too.
Matt Foehr
executiveAlright, thank you, operator. We’re eager to talk about our second quarter financial results in a few months. In the meantime, over the coming weeks, we’ll take part in some investor conferences, including Benchmark’s Healthcare House Call Virtual Investor Conference later this month, and then we’ll also attend the Jefferies Global Healthcare Conference in New York City in June. So we hope to see some of you there. Thanks again for joining our call, and have a great day.
Operator
operatorThis concludes today's call. Thank you for attending. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete OmniAb, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to OmniAb, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in OmniAb, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.